Keywords: Johnson & Johnson, Risperfal, Marketing practices, USA, Justice Department, SEC, Teva, Subpoenaed

Johnson & Johnson close to settling over Risperdal marketing; SEC probes Teva

Article | 06 August 2012

Print This

US health care giant Johnson & Johnson (NYSE: JNJ) has reached “an agreement in principle’’ with the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in